Results (Tables)

6 Months Ended

Jun. 30, 2019

Operating costs

Summary of research and development expenditure by program

	Six months ended June 30,
	2019		2018
	(Euro, in thousands)
Filgotinib program (partnered)	€	(30,406)	€	(32,210)
CF program (partnered)		(1,793)		(21,014)
IPF program on GLPG1690 (proprietary)		(41,668)		(24,107)
OA program on GLPG1972 (partnered)		(9,733)		(7,621)
AtD program on MOR106 (partnered)		(12,460)		(7,661)
Other		(81,507)		(58,832)
Total R&D expenditure	€	(177,567)	€	(151,444)